Company: Xcellerex
Based: Marlborough, MA
Amount: $41.84M
Round: Third
Investors: Biotechonomy Ventures, Kleiner Perkins Caufield & Byers, Undisclosed Investor, VantagePoint Venture Partners

Scoop: Xcellerex raised $41.84 million in two separate rounds last year. During the first round in January, the company raised $11 million to finance commercialization of a manufacturing program that uses disposable components to produce multiple products. In another round in October, Xellerex gained $31 million for "development and commercialization of its proprietary FlexFactory manufacturing system and XDR bioreactors for the production of biomolecules, including biotherapeutics and vaccines, and for developing its own internal biomolecule products."

More News:
Xcellerex gains $11M in new venture funds. Report


Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.